<DOC>
	<DOCNO>NCT01562288</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood DNA laboratory patient receive chemotherapy without trastuzumab may help doctor learn effect trastuzumab cell . It may also help doctor understand well patient respond treatment . PURPOSE : This research trial study blood DNA sample patient breast cancer treat chemotherapy without trastuzumab .</brief_summary>
	<brief_title>Studying Blood DNA Samples From Patients With Breast Cancer Treated With Chemotherapy With Without Trastuzumab</brief_title>
	<detailed_description>OBJECTIVES : - To determine role trastuzumab generation HER2-specific antibody breast cancer patient undergo adjuvant combination therapy . - To determine whether improved disease-free period overall survival patient treat adjuvant set combination chemotherapy trastuzumab dependent Fcγ receptor genotype patient . OUTLINE : Previously collect serum DNA sample analyze HER2-specific antibody FcγR genotype enzyme-linked immunosorbent assay ( ELISA ) polymerase chain reaction ( PCR ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>• Patients HER2overexpressing nodepositive highrisk nodenegative breast cancer enrol NCCTGN9831 * Pre posttreatment serum DNA sample patient treat doxorubicin cyclophosphamide follow paclitaxel without trastuzumab ( Herceptin® )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HER2-positive breast cancer</keyword>
	<keyword>HER2-negative breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>